April 2016 | Targeted Therapies in Oncology

Extended RESONATE Data Illuminates Ibrutinib's Benefits in High-Risk CLL

May 16, 2016

Clinical Articles

Extended follow-up data continue to demonstrate the efficacy and tolerability of ibrutinib in previously treated patients with chronic lymphocytic leukemia, including those with high-risk gene mutations and prognostic features.

Entrectinib Shows Dramatic Response in Rare Salivary Gland Tumor

May 09, 2016

Clinical Articles

The experimental targeted therapy entrectinib demonstrated a dramatic response in a patient with metastatic mammary analog secretory carcinoma (MASC), which is a rare form of salivary gland cancer.

Frontline Myeloma Therapies Undergoing Dramatic Transformation

May 05, 2016

Clinical Articles

The high level of efficacy observed with the combination of bortezomib, lenalidomide, and dexamethasone in the phase III SWOG S0777 study significantly changed the frontline treatment paradigm for patients with multiple myeloma.

Shortcomings in SIRFLOX Design May Have Skewed PFS Findings

May 03, 2016

Clinical Articles

Navesh K. Sharma, DO, PhD, discusses the addition of Yttrium-90 resin microspheres to standard frontline FOLFOX-based chemotherapy with or without bevacizumab in patients with liver metastatic colorectal cancer.

Novel BTK, PI3K Inhibitors on Horizon for Relapsed CLL

April 30, 2016

Clinical Articles

With nearly a dozen new PI3K and BTK inhibitors currently in development for patients with relapsed chronic lymphocytic leukemia it is challenging to know which therapies are truly "next-generation" agents and which are "me too" products.

New Mammography Guidelines Are Flawed

April 16, 2016

Clinical Articles

The breast cancer guidelines in the United States need to be fixed, which can only be accomplished by those on the frontlines. We need oncologists to chime into the discussion.